Predictive factors for the efficacy of brolucizumab in refractory polypoidal choroidal vasculopathy following aflibercept resistance
Eyes without marked early choroidal thinning (<40% CCT reduction at A1) were more likely to extend, whereas marked thinning (≥40%) signaled difficulty extending under T&E regimen after switching to brolucizumab. Given the small sample and few events, estimates should be interpreted cautiously and considered hypothesis-generating, and warrant prospective external validation studies.
Authors
- Shuichiro Aoki (ORCID: https://orcid.org/0000-0002-1766-4773)
- Akie Yoshinaga
- Tatsuya Inoue (ORCID: https://orcid.org/0000-0002-2481-0222)
- Ryo Terao (ORCID: https://orcid.org/0000-0001-6182-4343)
- Ryo Obata (ORCID: https://orcid.org/0000-0002-1762-0797)
- Kohdai Kitamoto (ORCID: https://orcid.org/0000-0003-1984-7984)
- Keiko Azuma (ORCID: https://orcid.org/0009-0007-9998-7448)
Institutions
- Yokohama City University Medical Center (JP)
- Showa General Hospital (JP)
- Toranomon Hospital (JP)
- The University of Tokyo (JP)
- Yokohama City University (JP)
Publication Details
- Journal
- PLoS ONE
- Published
- 2025-11-04
- DOI
- https://doi.org/10.1371/journal.pone.0326018
- Primary Topic
- Retinal Diseases and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00